Naloxone Diminishes the Virulence and Modifies the Cellular Immune Responses of BALB/c Mice Infected with Leishmania major.
BALB/c mice
Cutaneous leishmaniasis
Leishmania major
Naloxone
Journal
Acta parasitologica
ISSN: 1896-1851
Titre abrégé: Acta Parasitol
Pays: Switzerland
ID NLM: 9301947
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
30
05
2020
accepted:
29
10
2020
pubmed:
20
11
2020
medline:
19
8
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
Leishmania major-infected BALB/c mice display strong susceptibility to the infection due to the induction of Th2 response. The aim of this study was to assess the effects of naloxone on virulence of L. major in BALB/c mice and the ensued cellular immune response. The effects of injection of a single dose of naloxone in the footpad of L. major-infected BALB/c mice were investigated by evaluating the lesion sizes, the parasite burden, cell proliferation, secreted cytokines (IFN-γ, IL-4, IL-10 and IL-12) and their genes expressions due to naloxone treatment while the untreated mice were used as a control. Significantly lower lesion sizes and less parasite burden were measured in the treated mice. Significantly decreased productions of IFN-γ, IL-12, IL-4, and IL-10 were also observed in the treated mice at week 4 post-infection while the production IL-10 remained significantly hindered till 8 weeks post-infection. Our data indicated that although the treatment of L. major-infected BALB/c mice with a single dose of naloxone was unable to improve the cellular immune response, it led to lower virulence, confirmed by significantly reduced lesions and parasite load.
Identifiants
pubmed: 33211271
doi: 10.1007/s11686-020-00308-w
pii: 10.1007/s11686-020-00308-w
doi:
Substances chimiques
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-523Subventions
Organisme : Pasteur Institute of Iran
ID : IPI-384
Références
Muller I, Fruth U, Louis JA (1992) Immunobiology of experimental leishmaniasis. Med Microbiol Immunol 181(1):1–12. https://doi.org/10.1007/BF00193391
doi: 10.1007/BF00193391
pubmed: 1349724
Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2(11):845–858. https://doi.org/10.1038/nri933
doi: 10.1038/nri933
pubmed: 12415308
Reiner SL, Locksley RM (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13:151–177. https://doi.org/10.1146/annurev.iy.13.040195.001055
doi: 10.1146/annurev.iy.13.040195.001055
pubmed: 7612219
Launois P, Maillard I, Pingel S, Swihart KG, Xenarios I, Acha-Orbea H, Diggelmann H, Locksley RM, MacDonald HR, Louis JA (1997) IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6(5):541–549. https://doi.org/10.1016/s1074-7613(00)80342-8
doi: 10.1016/s1074-7613(00)80342-8
pubmed: 9175832
Launois P, Tacchini-Cottier F, Parra-Lopez C, Louis JA (1998) Cytokines in parasitic diseases: the example of cutaneous Leishmaniasis. Int Rev Immunol 17(1–4):157–180. https://doi.org/10.3109/08830189809084491
doi: 10.3109/08830189809084491
pubmed: 9914947
Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG (2002) Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 209(1):1–7. https://doi.org/10.1111/j.1574-6968.2002.tb11101.x
doi: 10.1111/j.1574-6968.2002.tb11101.x
pubmed: 12007646
Robinson A, Wermeling DP (2014) Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm 71(24):2129–2135. https://doi.org/10.2146/ajhp130798
doi: 10.2146/ajhp130798
pubmed: 25465584
Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF (1987) Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest 80(3):824–831. https://doi.org/10.1172/JCI113140
doi: 10.1172/JCI113140
pubmed: 3040807
pmcid: 442309
Bhaskaran M, Reddy K, Sharma S, Singh J, Radhakrishnan N, Kapasi A, Singhal PC (2001) Morphine-induced degradation of the host defense barrier: role of macrophage injury. J Infect Dis 184(12):1524–1531. https://doi.org/10.1086/324667
doi: 10.1086/324667
pubmed: 11740727
Azuma Y, Ohura K (2002) Endomorphin-2 modulates productions of TNF-alpha, IL-1beta, IL-10, and IL-12, and alters functions related to innate immune of macrophages. Inflammation 26(5):223–232. https://doi.org/10.1023/a:1019766602138
doi: 10.1023/a:1019766602138
pubmed: 12238565
Narayan P, Tandon R, Haq W, Dhar MM, Singh VK (2002) Inhibition of antigen specific lymphocyte proliferation and cytokine stimulation by peptidomimetic opioid compound. Int Immunopharmacol 2(6):751–757. https://doi.org/10.1016/s1567-5769(02)00011-5
doi: 10.1016/s1567-5769(02)00011-5
pubmed: 12095165
Loizzo A, Loizzo S, Lopez L, d’Amore A, Renzi P, Spampinato S, Di Carlo S, Bacosi A, Zuccaro P, Pacifici R (2002) Naloxone prevents cell-mediated immune alterations in adult mice following repeated mild stress in the neonatal period. Br J Pharmacol 135(5):1219–1226. https://doi.org/10.1038/sj.bjp.0704577
doi: 10.1038/sj.bjp.0704577
pubmed: 11877330
pmcid: 1573241
Molla Hassan AT, Hassan ZM, Moazzeni SM, Mostafaie A, Shahabi S, Ebtekar M, Hashemi SM (2009) Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice. Int Immunopharmacol 9(12):1381–1386. https://doi.org/10.1016/j.intimp.2009.08.008
doi: 10.1016/j.intimp.2009.08.008
pubmed: 19706340
Sacerdote P, Manfredi B, Gaspani L, Panerai AE (2000) The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 95(6):2031–2036
doi: 10.1182/blood.V95.6.2031
Titus RG, Marchand M, Boon T, Louis JA (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7(5):545–555. https://doi.org/10.1111/j.1365-3024.1985.tb00098.x
doi: 10.1111/j.1365-3024.1985.tb00098.x
pubmed: 3877902
Asadpour A, Riazi-Rad F, Khaze V, Ajdary S, Alimohammadian MH (2013) Distinct strains of Leishmania major induce different cytokine mRNA expression in draining lymph node of BALB/c mice. Parasite Immunol 35(1):42–50. https://doi.org/10.1111/pim.12018
doi: 10.1111/pim.12018
pubmed: 23106526
Darabi S, Khaze V, Riazi-Rad F, Darabi H, Bahrami F, Ajdary S, Alimohammadian MH (2015) Leishmania major strains isolated from distinct endemic areas show diverse cytokine mRNA expression levels in C57BL/6 mice: toward selecting an ideal strain for the vaccine studies. Cytokine 76(2):303–308. https://doi.org/10.1016/j.cyto.2015.05.022
doi: 10.1016/j.cyto.2015.05.022
pubmed: 26072430
Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C (2003) The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 14(1):33–43
pubmed: 12901609
pmcid: 2279895
Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H (2006) Quantitative real-time RT-PCR data analysis: current concepts and the novel “gene expression’s CT difference” formula. J Mol Med (Berl) 84(11):901–910. https://doi.org/10.1007/s00109-006-0097-6
doi: 10.1007/s00109-006-0097-6
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
pubmed: 11846609
pmcid: 11846609
Rao Y, Wang YL, Li JG, Ke JJ (2004) Effects of morphine and fentanyl on tumor necrosis factor-alpha and interleukin-6 concentrations in human whole blood in vitro. Chin Med J (Engl) 117(2):303–304
Karaji AG, Hamzavi Y (2012) The opioid antagonist naloxone inhibits Leishmania major infection in BALB/c mice. Exp Parasitol 130(1):73–77. https://doi.org/10.1016/j.exppara.2011.09.006
doi: 10.1016/j.exppara.2011.09.006
pubmed: 22019408
Bozorgomid A, Hajipirloo HM, Tappeh KH, Nazari N, Karamati SA, Shirooie S (2016) Evaluation of the alum-naloxone adjuvant activity against experimental murine leishmaniasis due to L. major. J Parasit Dis 40(4):1141–1145. https://doi.org/10.1007/s12639-015-0731-8
doi: 10.1007/s12639-015-0731-8
pubmed: 27876902
pmcid: 5118357